Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP, Grannis SJ, Ong TC, Ball SW, DeSilva MB, Natarajan K, Sheffield T, Bride D, Arndorfer J, Naleway AL, Koppolu P, Fireman B, Zerbo O, Timbol J, Goddard K, Dixon BE, Fadel WF, Rogerson C, Allen KS, Rao S, Mayer D, Barron M, Reese SE, Rowley EAK, Najdowski M, Ciesla AA, Mak J, Reeves EL, Akinsete OO, McEvoy CE, Essien IJ, Tenforde MW, Fleming-Dutra KE, Link-Gelles R. Payne AB, et al. Among authors: mayer d. Lancet. 2024 Oct 19;404(10462):1547-1559. doi: 10.1016/S0140-6736(24)01738-0. Lancet. 2024. PMID: 39426837
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024.
DeCuir J, Payne AB, Self WH, Rowley EAK, Dascomb K, DeSilva MB, Irving SA, Grannis SJ, Ong TC, Klein NP, Weber ZA, Reese SE, Ball SW, Barron MA, Naleway AL, Dixon BE, Essien I, Bride D, Natarajan K, Fireman B, Shah AB, Okwuazi E, Wiegand R, Zhu Y, Lauring AS, Martin ET, Gaglani M, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker M, Mohamed A, Srinivasan V, Steingrub JS, Khan A, Busse LW, Duggal A, Wilson JG, Chang SY, Mallow C, Kwon JH, Exline MC, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Casey JD, Chappell JD, Grijalva CG, Swan SA, Johnson C, Lewis NM, Ellington S, Adams K, Tenforde MW, Paden CR, Dawood FS, Fleming-Dutra KE, Surie D, Link-Gelles R; CDC COVID-19 Vaccine Effectiveness Collaborators. DeCuir J, et al. MMWR Morb Mortal Wkly Rep. 2024 Feb 29;73(8):180-188. doi: 10.15585/mmwr.mm7308a5. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38421945 Free PMC article.
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.
Aggarwal NR, Beaty LE, Bennett TD, Fish LE, Jacobs JR, Mayer DA, Molina KC, Peers JL, Richardson DB, Russell S, Varela A, Webb BJ, Wynia MK, Xiao M, Carlson NE, Ginde AA. Aggarwal NR, et al. Among authors: mayer da. Lancet Reg Health Am. 2024 Feb 9;31:100693. doi: 10.1016/j.lana.2024.100693. eCollection 2024 Mar. Lancet Reg Health Am. 2024. PMID: 38500962 Free PMC article.
Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Wynia MK, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Stocker HR, Wogu AF, Zane RD, Sokol RJ, Ginde AA. Wynia MK, et al. Among authors: mayer da. medRxiv [Preprint]. 2022 Jan 11:2022.01.09.22268963. doi: 10.1101/2022.01.09.22268963. medRxiv. 2022. Update in: J Infect Dis. 2022 Dec 13;226(12):2129-2136. doi: 10.1093/infdis/jiac206 PMID: 35043117 Free PMC article. Updated. Preprint.
Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Wogu AF, Wynia MK, Zane RD, Ginde AA. Aggarwal NR, et al. Among authors: mayer da. medRxiv [Preprint]. 2022 Apr 5:2022.04.03.22273360. doi: 10.1101/2022.04.03.22273360. medRxiv. 2022. Update in: J Infect Dis. 2022 Dec 13;226(12):2129-2136. doi: 10.1093/infdis/jiac206 PMID: 35411339 Free PMC article. Updated. Preprint.
Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Molina KC, Peers JL, Russell S, Wynia MK, Ginde AA. Aggarwal NR, et al. Among authors: mayer da. Int J Infect Dis. 2023 Mar;128:310-317. doi: 10.1016/j.ijid.2022.10.002. Epub 2022 Oct 10. Int J Infect Dis. 2023. PMID: 36229005 Free PMC article.
Effectiveness of subcutaneous monoclonal antibody treatment in emergency department outpatients with COVID-19.
Wendel SK, Wogu AF, Carlson NE, Beaty L, Bennett TD, Bookman K, Mayer DA, Michael SM, Molina KC, Peers JL, Russell S, Zane RD, Ginde AA. Wendel SK, et al. Among authors: mayer da. J Am Coll Emerg Physicians Open. 2024 Feb 21;5(1):e13116. doi: 10.1002/emp2.13116. eCollection 2024 Feb. J Am Coll Emerg Physicians Open. 2024. PMID: 38384380 Free PMC article.
A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies.
Xiao M, Molina KC, Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Fish LE, Hamer MK, Kwan BM, Mayer DA, Peers JL, Wynia MK, Ginde AA. Xiao M, et al. Among authors: mayer da. JAMA Health Forum. 2024 Sep 6;5(9):e242884. doi: 10.1001/jamahealthforum.2024.2884. JAMA Health Forum. 2024. PMID: 39269694 Free PMC article.
1,576 results